| Followers | 45 |
| Posts | 129 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2021 |
Thursday, March 20, 2025 7:07:49 PM
I'm not about to try to convince you or anyone else that they should give credence to my observations; everyone reading this is free to draw their own conclusions about the motivations and relative trustworthiness of anonymous message board posters. But I would like to point out that you have left out the context of each of these quotes.
The first quote is from a post on 10/24/24. This was more than a month before the June CHM minutes were released, in which we first learned the date of DCVax-L's first meeting. The post spells out the assumptions upon which my projections were given.
The second quote is from a post on 12/31/24. In context, you'll see that this specifically refers to the fact that there was less lead time between the submission of DCVax-L's MAA and its first CHM meeting than there was for other drugs. This is a true statement.
The third quote is from a post on 2/4/25. The timeframe mentioned in it refers to something I mentioned in another post on the same day, in which I gave a specific date (5/6/25) after which our application would officially be in unprecedented territory. I stand by that date as a point at which I personally would begin to feel worried about how long it was taking (even though, since that time, mRESVIA received approval with an even longer timeline).
Over the past ~4 months, new information has periodically emerged via CHM minutes and MHRA approvals. I don't change my statements because things "looked dark" – I update my observations when new information is available, and acknowledge errors when I make them. To each their own, but that is the approach I personally prefer to take, as opposed to omitting details in order to make a point.
The first quote is from a post on 10/24/24. This was more than a month before the June CHM minutes were released, in which we first learned the date of DCVax-L's first meeting. The post spells out the assumptions upon which my projections were given.
The second quote is from a post on 12/31/24. In context, you'll see that this specifically refers to the fact that there was less lead time between the submission of DCVax-L's MAA and its first CHM meeting than there was for other drugs. This is a true statement.
The third quote is from a post on 2/4/25. The timeframe mentioned in it refers to something I mentioned in another post on the same day, in which I gave a specific date (5/6/25) after which our application would officially be in unprecedented territory. I stand by that date as a point at which I personally would begin to feel worried about how long it was taking (even though, since that time, mRESVIA received approval with an even longer timeline).
Over the past ~4 months, new information has periodically emerged via CHM minutes and MHRA approvals. I don't change my statements because things "looked dark" – I update my observations when new information is available, and acknowledge errors when I make them. To each their own, but that is the approach I personally prefer to take, as opposed to omitting details in order to make a point.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
